|
|
|
|
Pharming Group (PHGUF.PK) Announces Euro 9 Million Debt Reduction And Continued Equity Financing With Ya Globa
- Biotech company Pharming Group NV ('Pharming') (NYSE Euronext: PHARM) announced today a further reduction of its outstanding amount of convertible debt and the further strengthening of its cash position under the agreement with YA Global...
|
|
|
Pharming announces Euro 9 million debt reduction and continued equity financing with Ya Global
Biotech company Pharming Group NV ('Pharming') (NYSE Euronext: PHARM) announced today a further reduction of its outstanding amount of convertible debt and the further strengthening of its cash position under the agreement with YA Global...
|
|
|
Pharming Receives Agreement on Paediatric Investigation Plan for Rhucin From the EMEA Paediatric Committe
Biotech company Pharming Group NV ('Pharming' or 'the Company') (NYSE Euronext: PHARM) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMEA) has adopted an opinion agreeing the paediatric investigation...
|
|
|
Pharming Provides Update On Number Of Outstanding Shares
Biotech company Pharming Group NV (Pharming or the Company) (NYSE Euronext: PHARM) today provided an update on the increased number of outstanding shares following the purchase by YA Global Master SPV LTD (YA Global) of newly issued Pharming...
|
|
|
Pharming Group (PHGUF.PK) Provides Update On Number Of Outstanding Shares
Biotech company Pharming Group NV ('Pharming' or 'the Company') (NYSE Euronext: PHARM) today provided an update on the increased number of outstanding shares following the purchase by YA Global Master SPV LTD ('YA Global') of newly issued...
|
|
|
Xeroderma pigmentosum with significant periodontal findings: a rare clinical report
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Periodontal Practice Today, 06/05/09 Print Save in My Library Free Abstract Pradeep AR et al.- Xeroderma pigmentosum (XP) is a very rare skin disorder...
|
|
|
Pharming Group's Prodarsan product gets orphan drug status from US FDA
Biotech company Pharming Group NV announced that its wholly-owned subsidiary DNage BV has received a notice from the US Food and Drug Administration that its product Prodarsan has been awarded an orphan drug designation for the treatment of ...
|
|
|
Pharming's Prodarsan obtains orphan drug status
Prodarsan, combination of two small molecules, formulated for oral use, believed to reduce the accumulation of DNA-damage Top Stories Conbriza, a selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis in women...
|
|
|
Prodarsan granted Orphan Drug designation from FDA
Biotech company Pharming Group NV ('Pharming' or 'the Company') (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage BV ('DNage') has received a notice from the US Food and Drug Administration ('FDA') that its...
|
|
|
Prodarsan(R) granted Orphan Drug designation from FDA
2009-04-2706:45ET - News Release LEIDEN, NETHERLANDS -- (MARKET WIRE) -- 04/27/09 Biotech company Pharming Group NV ('Pharming' or 'the Company') (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage BV ('DNage') has...
|
|
|
UPDATE 1-Pharming drug gets FDA orphan status, shares jump
* Drug targets premature aging in children * Status allows accelerated review, market exclusivity * Shares up 26 pct, from being flat before statement (Writes through, adds detail) AMSTERDAM, April 27 (Reuters) - Dutch biotechnology firm...
|
